Advertisement

Treatment of hirsutism with myo-inositol: a prospective clinical study

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The aim of this study was to evaluate the effects of myo-inositol treatment in hirsute women; changes in lipid pattern and insulin sensitivity were also considered. Forty-six hirsute women were enrolled at the first Institute of Obstetrics and Gynecology and evaluated at baseline and after receiving myo-inositol therapy for 6 months. Body mass index (BMI), hirsutism, serum concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, apolipoprotein B, lipoprotein(a), serum adrenal and ovarian androgens, fasting glucose and insulin concentrations were evaluated. No changes in BMI were observed. The hirsutism decreased after therapy (P < 0.001). Total androgens, FSH and LH concentrations decreased while oestradiol concentrations increased. There was a slight non-significant decrease in total cholesterol concentrations, an increase in HDL cholesterol concentrations and a decrease in LDL cholesterol concentrations. No significant changes were observed in serum triglyceride, apolipoprotein B and lipoprotein(a) concentrations. Insulin resistance (P < 0.01), analysed by homeostasis model assessment, was reduced significantly after therapy. Administration of oral myo-inositol significantly reduced hirsutism and hyperandrogenism and ameliorated the abnormal metabolic profile of women with hirsutism.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Azziz R
        PCOS: a diagnostic challenge.
        Reproductive BioMedicine Online. 2004; 8: 644-648
        • Azziz R
        The evaluation and management of hirsutism.
        Obstetrics and Gynecology. 2003; 101: 995-1007
        • Baillargeon JP
        Use of insulin sensitizers in polycystic ovarian syndrome.
        Current Opinion in Investigational Drugs. 2005; 6: 1012-1022
        • Baillargeon JP
        • Kandarakis ED
        • Ostlund RE
        • et al.
        Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
        Diabetes Care. 2006; 29: 300-305
        • Cheang KI
        • Nestler JE
        Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?.
        Reproductive BioMedicine Online. 2004; 8: 440-447
        • Escobar-Morreale HF
        • Lasunción MA
        • Sancho J
        Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity.
        Fertility and Sterility. 2000; 74: 816-819
        • Ferriman D
        • Gallwey JD
        Clinical assessment of body hair growth in women.
        Journal of Clinical Endocrinology. 1961; 21: 1440-1447
        • Geisthövel F
        • Rabe T
        The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS): an extended critical analysis.
        Reproductive BioMedicine Online. 2007; 14: 522-535
        • Gerli S
        • Mignosa M
        • Di Renzo GC
        Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial.
        European Review for Medical and Pharmacological Sciences. 2003; 7: 151-159
        • Iuorno MJ
        • Jacubowicz DJ
        • Baillargeon JP
        • et al.
        Effect of d-chiro-inositol in lean women with the polycystic ovary syndrome.
        Endocrine Practice. 2002; 8: 417-423
        • Krauss RM
        • Burkman Jr, RT
        The metabolic impact of oral contraceptives.
        American Journal of Obstetrics and Gynecology. 1992; 167: 1177-1184
        • Nestler JE
        • Jacubowicz DJ
        Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
        Journal of Clinical Endocrinology and Metabolism. 1997; 82: 4075-4079
        • Nestler JE
        • Jakubowicz DJ
        • Reamer P
        • et al.
        Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome.
        New England Journal of Medicine. 1999; 340: 1314-1320
        • Papaleo E
        • Unfer V
        • Baillargeon JP
        • et al.
        Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
        Gynecologic Endocrinology. 2007; 10: 1-4
        • Proctor SD
        • Kelly SE
        • Vine DF
        • Russell JC
        Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant.
        Metabolism. 2007; 56: 1318-1325
        • Yoshida K
        • Yamaguchi M
        • Morinaga T
        • et al.
        Genetic modification of Bacillus subtilis for production of d-chiro-inositol, an investigation drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome.
        Applied and Environmental Microbiology. 2006; 72: 1310-1315

      Biography

      Vittorio Unfer is a gynaecologist specializing in the fields of reproductive endocrinology and clinical infertility for the last 15 years. He was born in Rome in 1963. He received his MD from the Università di Roma ‘La Sapienza’, where he has been an active professor since 1999, and continued his DSc in gynaecology there. Dr Unfer is the author of more than 100 articles in national and international scientific publications and has participated as a guest speaker in more than 30 meetings concerning specific topics in gynaecology. Since 2000, Dr Unfer has been cited in Who's Who in the World. Currently his research interests are related to gynaecological endocrinology and reproductive and perinatal endocrinology.